On September 19th, Bloomage Biotech stated in its investor relations activity record that the company currently has 7-8 ongoing research projects on collagen. They have successfully achieved the production of recombinant collagen with large molecules and launched the market for recombinant Type III human collagen raw material products in August. The next step will be to steadily advance the application of self-produced recombinant human collagen raw materials in skincare products.
Regarding the adjustment direction of the company’s skincare segment in the second half of the year, Bloomage Biotech mentioned that the functional skincare business has experienced high-speed growth over the past 3-4 years and has gained a certain level of market recognition. However, transitioning from being a large-scale brand to becoming a true national brand is still a long and challenging journey. The company has room for optimization and adjustment in terms of product offerings, channel strategies, and brand positioning.
In the second half of 2023, Bloomage Biotech will continue to focus on brand positioning, optimizing the channel structure, strengthening the strategy of flagship products, and enhancing digital operations. They aim to continuously enhance organizational capabilities and improve the level of refined operational management.
Specifically, at the product level, they will continue to develop flagship products and product series, increase the proportion of flagship products and product series, and rely on stable repurchases of flagship products to provide a solid business foundation for the brand. At the channel level, they will optimize the channel structure, increase the proportion of self-owned channels, reduce reliance on other channels, and enhance the brand’s ability to withstand risks in the distribution network. At the brand level, they will sharpen the brand’s positioning, make the brand image more distinct and recognizable, and focus on capturing the mindshare of core customers. Through various measures, they aim to better respond to market challenges and promote business growth.
Additionally, Bloomage Biotech also stated that in the first half of 2023, the company had approximately 3,500 active sales outlets in its offline medical aesthetics channels, with an increase of over 1,000 compared to the previous year.
In the future, the company will continue to improve the coverage and repurchase rates in terminal outlets, further optimize the ratio between direct sales and distribution channels. For key customers, they will continue to increase the proportion of direct sales and strengthen the company’s service capabilities for these customers. For medium and small customers, the company will continuously improve coverage through distribution channels, enhance the service capabilities of distributors, and ensure that customers enjoy high-quality products and services.
